Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0817 | 0.3749 | 0.3739 |
Toxoplasma gondii | ran binding protein | 0.0291 | 0.1161 | 0.3069 |
Onchocerca volvulus | Apolipophorins homolog | 0.1185 | 0.5558 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0817 | 0.3749 | 0.3739 |
Echinococcus multilocularis | zinc finger protein Ran binding | 0.0291 | 0.1161 | 0.1148 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 0.1161 | 0.1161 |
Schistosoma mansoni | hypothetical protein | 0.0817 | 0.3749 | 0.3739 |
Loa Loa (eye worm) | brahma associated protein | 0.0817 | 0.3749 | 0.3749 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0291 | 0.1161 | 1 |
Giardia lamblia | UDP-glucose 4-epimerase | 0.0089 | 0.0169 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0817 | 0.3749 | 1 |
Schistosoma mansoni | hypothetical protein | 0.2088 | 1 | 1 |
Echinococcus granulosus | UDP glucose 4 epimerase | 0.0085 | 0.0152 | 0.0137 |
Entamoeba histolytica | UDP-glucose 4-epimerase, putative | 0.0085 | 0.0152 | 0.5 |
Toxoplasma gondii | UDP-glucose 4-epimerase | 0.0085 | 0.0152 | 0.0367 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 0.1161 | 0.1161 |
Schistosoma mansoni | hypothetical protein | 0.0817 | 0.3749 | 0.3739 |
Leishmania major | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 0.1161 | 0.1161 |
Brugia malayi | YY1-associated factor 2 | 0.0291 | 0.1161 | 0.3097 |
Schistosoma mansoni | fusion | 0.0291 | 0.1161 | 0.1148 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0291 | 0.1161 | 0.3097 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 0.1161 | 0.1161 |
Mycobacterium leprae | HOLO-[ACYL-CARRIER PROTEIN] SYNTHASE ACPS (HOLO-ACP SYNTHASE) (CoA:APO-[ACP]PANTETHEINEPHOSPHOTRANSFERASE) (CoA:APO-[ACYL-CARRIE | 0.0087 | 0.0161 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0291 | 0.1161 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Mycobacterium tuberculosis | holo-[acyl-carrier protein] synthase AcpS (holo-ACP synthase) (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrie | 0.0109 | 0.0267 | 1 |
Echinococcus multilocularis | ring and YY1 binding protein | 0.0291 | 0.1161 | 0.1148 |
Onchocerca volvulus | 0.0817 | 0.3749 | 0.5884 | |
Echinococcus granulosus | zinc finger protein Ran binding | 0.0291 | 0.1161 | 0.1148 |
Schistosoma mansoni | zinc finger protein | 0.0291 | 0.1161 | 0.1148 |
Schistosoma mansoni | RNA binding protein | 0.0291 | 0.1161 | 0.1148 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0817 | 0.3749 | 0.3749 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0291 | 0.1161 | 1 |
Schistosoma mansoni | TRABID protein (C64 family) | 0.0291 | 0.1161 | 0.1148 |
Schistosoma mansoni | UDP-glucose 4-epimerase | 0.0085 | 0.0152 | 0.0137 |
Schistosoma mansoni | hypothetical protein | 0.0291 | 0.1161 | 0.1148 |
Echinococcus multilocularis | Nuclear pore complex protein Nup153 | 0.0291 | 0.1161 | 0.1148 |
Schistosoma mansoni | brg-1 associated factor | 0.0817 | 0.3749 | 0.3739 |
Leishmania major | udp-glc 4-epimerase, putative | 0.0089 | 0.0169 | 0.1344 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0817 | 0.3749 | 1 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0817 | 0.3749 | 1 |
Echinococcus granulosus | ring and YY1 binding protein | 0.0291 | 0.1161 | 0.1148 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0291 | 0.1161 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0291 | 0.1161 | 0.3097 |
Treponema pallidum | 4'-phosphopantetheinyl transferase | 0.0109 | 0.0267 | 0.5 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0291 | 0.1161 | 1 |
Echinococcus multilocularis | microsomal triglyceride transfer protein large | 0.2088 | 1 | 1 |
Brugia malayi | UDP galactose 4'-epimerase | 0.0085 | 0.0152 | 0.0405 |
Loa Loa (eye worm) | hypothetical protein | 0.0291 | 0.1161 | 0.1161 |
Leishmania major | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Echinococcus multilocularis | UDP glucose 4 epimerase | 0.0085 | 0.0152 | 0.0137 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0817 | 0.3749 | 0.3739 |
Echinococcus multilocularis | Zinc finger, RanBP2 type | 0.0291 | 0.1161 | 0.1148 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0817 | 0.3749 | 0.3739 |
Plasmodium falciparum | zinc finger Ran-binding domain-containing protein 2, putative | 0.0291 | 0.1161 | 0.2567 |
Brugia malayi | brahma associated protein 60 kDa | 0.0817 | 0.3749 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Echinococcus multilocularis | Lipid transport protein, N terminal | 0.1185 | 0.5558 | 0.5552 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0817 | 0.3749 | 1 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0291 | 0.1161 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0817 | 0.3749 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0817 | 0.3749 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2088 | 1 | 1 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0817 | 0.3749 | 1 |
Loa Loa (eye worm) | UDP galactose 4'-epimerase | 0.0085 | 0.0152 | 0.0152 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0817 | 0.3749 | 0.3739 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0817 | 0.3749 | 1 |
Wolbachia endosymbiont of Brugia malayi | 4'-phosphopantetheinyl transferase | 0.0109 | 0.0267 | 0.5 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0291 | 0.1161 | 0.3097 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0817 | 0.3749 | 1 |
Chlamydia trachomatis | SWIB complex protein | 0.0817 | 0.3749 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0817 | 0.3749 | 0.3739 |
Echinococcus granulosus | Zinc finger RanBP2 type | 0.0291 | 0.1161 | 0.1148 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Toxoplasma gondii | Zn-finger in Ran binding protein and others domain-containing protein | 0.0291 | 0.1161 | 0.3069 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0291 | 0.1161 | 1 |
Echinococcus granulosus | Lipid transport protein N terminal | 0.1185 | 0.5558 | 0.5552 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0817 | 0.3749 | 0.3739 |
Leishmania major | hypothetical protein, conserved | 0.0291 | 0.1161 | 1 |
Mycobacterium ulcerans | 4'-phosphopantetheinyl transferase | 0.0109 | 0.0267 | 1 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0291 | 0.1161 | 1 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0291 | 0.1161 | 0.3097 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.0291 | 0.1161 | 1 |
Echinococcus granulosus | Nuclear pore complex protein Nup153 | 0.0291 | 0.1161 | 0.1148 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0817 | 0.3749 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1185 | 0.5558 | 0.5558 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.159 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.